Early initiation of tolvaptan is associated with early discharge in patients with heart failure regardless of age [PDF]
, 2022 Shunsuke Kiuchi +7 more
openalex +1 more source
Loop Diuretic Therapy in Severe Aortic Stenosis: Marker or Mediator of Adverse Outcomes?
Clinical Cardiology, Volume 49, Issue 1, January 2026.
Masaki Miyazawa, Teruhiko Imamura
wiley +1 more source
Advanced Science, Volume 12, Issue 36, September 25, 2025.This review explores the transformative potential of lipid‐based nanoparticles (LNPs) in renal cell carcinoma (RCC) therapy. It systematically analyzes six LNP platforms‐from liposomes to hybrid nanoparticles‐highlighting their unique advantages in targeted drug delivery, resistance reversal, and immunomodulation.
Wei Yao +7 more
wiley +1 more source
Diabetes, Obesity and Metabolism, Volume 27, Issue S8, Page 15-33, September 2025.Abstract Albuminuria, the abnormal presence of albumin in urine, is a key marker of kidney damage and a strong predictor of kidney and cardiovascular outcomes. Its clinical significance has evolved from early historical observations to its current role in chronic kidney disease (CKD) detection, risk stratification and treatment monitoring.
Jelle M. Beernink +4 more
wiley +1 more source
BMC Gastroenterology, 2020 Background To determine the safety and efficacy of different doses of tolvaptan for treating Chinese cirrhotic patients with or without hyponatraemia who still had ascites after routine therapy with diuretics.
Jieting Tang +19 more
doaj +1 more source
PLoS ONE, 2017 AimsSeveral studies reported treatment benefits of tolvaptan in patients with congestive heart failure (CHF). However, the optimal dosage remains unclear.
Mei-Yi Wu +6 more
doaj +1 more source
Tolvaptan for Primary Aldosteronism and Autosomal Dominant Polycystic Kidney Disease: A Case Report
Case Reports in Nephrology and Dialysis, 2018 A 59-year-old Japanese woman was admitted for evaluation of muscle weakness. Autosomal dominant polycystic kidney disease had been diagnosed at the age of 47 years, followed by primary aldosteronism at 53 years.
Kyohei Kunizawa +14 more
doaj +1 more source
Terapia diuretica nell’insufficienza cardiaca cronica: evidenze, esperienze, prospettive = Diuretic treatment in patients with chronic heart failure: evidences, experiences, and current perspectives [PDF]
, 2017 Congestion is a fundamental clinical sign in patients with chronic heart failure (CHF). Diuretics are the mainstay treatment for congestion but, so far, no randomized trial has ever shown any beneficial effect of diuretics on mortality in patients with ...
Carubelli, Valentina +1 more
core +1 more source
Assessing and grading congestion in acute heart failure: a scientific statement from the acute heart failure committee of the heart failure association of the European society of cardiology and endorsed by the European society of intensive care medicine [PDF]
, 2010 Patients with acute heart failure (AHF) require urgent in-hospital treatment for relief of symptoms. The main reason for hospitalization is congestion, rather than low cardiac output. Although congestion is associated with a poor prognosis, many patients
Anker SD +23 more
core
Propagation of Pericentral Necrosis During Acetaminophen-Induced Liver Injury: Evidence for Early Interhepatocyte Communication and Information Exchange. [PDF]
, 2019 Acetaminophen (APAP)-induced liver injury is clinically significant, and APAP overdose in mice often serves as a model for drug-induced liver injury in humans.
Hunt, C Anthony +5 more
core